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Abstract
Cerebrovascular disease involve the alterations caused by pathology process of the sanguineous 
vessels, affecting one or many brain areas. Cerebrovascular disease is also known like stroke or 
ictus; it is the third cause of death around the world and is the neurologic pathology with the 
most prevalence rate. Cerebrovascular disease induces several changes in genetic expression 
inside the neurovascular unit (glia cells, neurons and ependymal cells); principally, changes in 
the oxidative stress and calcium inflow into the cells, this could start cellular death and tissue 
destruction, causing an irreversible injury in brain, losing several functions. The injury causes 
the activation of signaling pathways to respond to the stress, where many molecules such as 
proteins and mRNA are involved to act as intermediaries to activate or deactivate stress me-
chanisms; these molecules are able to transmit extracellular signals into the nucleus activating 
early gene expression like proto-oncogenes and several transcription factors to repair the cerebral 
injury. It is important to know the relation of the changes in genetic expression and proteins 
to avoid the development of injury and to activate the brain recovery. This knowledge let us 
diagnose the injury rate and propose therapeutic mechanisms to reduce or avoid the adverse 
effects on time, before the cellular death start. 
Key words: Cellular adaptation, cerebrovascular disease, genetic expression, experi-
mental models.
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Resumen
Las enfermedades cerebrovasculares implican las alteraciones causadas por el proceso patológico 
de los vasos sanguíneos, que afectan a una o varias áreas del cerebro. La enfermedad cerebro-
vascular también se conoce como ictus o ictus; Es la tercera causa de muerte en todo el mundo 
y es la patología neurológica con mayor tasa de prevalencia. La enfermedad cerebrovascular 
induce varios cambios en la expresión genética dentro de la unidad neurovascular (células 
gliales, neuronas y células ependimales); Principalmente, los cambios en el estrés oxidativo 
y la entrada de calcio en las células, podrían iniciar la muerte celular y la destrucción del 
tejido, causando una lesión irreversible en el cerebro, perdiendo varias funciones. La lesión 
hace que la activación de las vías de señalización responda al estrés, donde muchas molécu-
las, como las proteínas y el ARNm, actúan como intermediarios para activar o desactivar los 
mecanismos de estrés; estas moléculas son capaces de transmitir señales extracelulares en 
el núcleo activando la expresión génica temprana como protooncogenes y varios factores de 
transcripción para reparar la lesión cerebral. Es importante conocer la relación de los cam-
bios en la expresión genética y las proteínas para evitar el desarrollo de lesiones y activar la 
recuperación del cerebro. Este conocimiento nos permite diagnosticar la tasa de lesiones y 
proponer mecanismos terapéuticos para reducir o evitar los efectos adversos a tiempo, antes 
de que comience la muerte celular.
Palabras clave: adaptación celular, enfermedad cerebrovascular, expresión genética, 
modelos experimentales..
CEREBROVASCULAR DISEASE
The right cell and organs function depends on a 
constant sanguineous flow to supply oxygen and 
nutrients to keep a right hydric balance and delete 
the toxic metabolic residues to the organism (1,2). 
The altered vascular permeability could produce 
injury even with intact sanguineous flow (3).
Vascular cerebral disease (CVD) is any brain 
alteration produced by a pathological process 
in sanguineous vessels (4). The Latin term 
“Ictus” means “stroke”, and involves all these 
pathologies, specifically when the symptoms are 
sudden and acute (5). According to their nature, 
CVD could be a deficiency in the flow caused by 
thrombosis or embolism (ischemia), also known 
commonly as cerebrovascular ischemic disease as 
well as hemorrhagic cerebral disease, caused in 
the parenchyma or inside the cerebral ventricles 
(cerebral hemorrhagic), or in the subarachnoid 
spice (subarachnoid hemorrhage), in a proportion 
of 85% and 15% respectively (figure 1) (3, 4, 6). 
The CVD is the third cause of mortality around 
the world (7) and recently in Mexico it rea-
ched the same position (8), just after cancer 
and heart disease (figure 2). In addition, is 
the most prevalent neurological pathology 
and one of the main causes of disability in 
the world (9, 10).
Cerebrovascular ischemic disease: cerebral 
ischemia
Cerebrovascular ischemic disease causes 
the decrease of glucose and oxygen in brain 
tissue. This could be in the whole brain, also 
known as global cerebral ischemia or in loca-
lized zones known as focal cerebral ischemia 
or multifocal if there are many zones affected. 
Specifically, in focal cerebral ischemia, if the 
ischemic process arises for 2-15 minutes it is 
a transitory ischemic attack or if the cellular 
death is present is a cerebral infarction where 
the sanguineous flow was restored during 
24 hours after the ischemic event. The reco-
very, of sanguineous reperfusion after the 
739Salud Uninorte. Barranquilla (Col.) 2018; 34 (3): 737-752
Applied genomic in cerebrovascular disease
ischemic attack is denominated sanguineous 
reperfusion, and sometimes, in many cases 
the damage is increased, since the cells have 
changed the mechanism for the adaptation 
against the hypoxia and the abrupt change 
in oxygen level is not supported by cells, 
increasing the production of reactive oxygen 
species and the oxidative stress originate in 
the ischemic zone. Then, the sanguineous flow 
recovery with respect to time, is essential for 
an adequate recuperation (5, 11). 
When the sanguineous flow stops the regu-
lated balance among the components of the 
neurovascular unit, the excitotoxity emerges 
in the cells , along with the oxidative stress, 
inflammation, intracellular signaling and 
neuronal death (12, 13). These events cause 
changes directly and indirectly in gene ex-
pression and in most cases as consequence, 
changes in protein levels (14, 15). 
GENETICS AND CEREBRAL ISCHEMIA
CVD induces changes in genetic expression 
related to repair and cell recovery (16). With 
ischemia, the energetic metabolism fails and 
the mRNA levels diminish severely in the ische-
mic zone (14, 17). On the other side, the early 
expression genes are activated and support 
the neuronal survival like c-fos, c-jun, jun-B, 
jun-D, krox-20, zif268 y homer 1a (18-22), that 
cause the expression of other genes through 
the protein-1 and the cAMP response element 
mainly, subsequently the heat shock proteins 
70 (HSP70) are expressed and many cytoki-
nes as tumoral necrosis factor alpha (TNFα), 
interleukin 1β (IL1β), interleukin 6 (IL6) and 
the quimiotactic peptide 1 of the monocyte 
(12, 23, 24). These cytokines induce the ad-
hesion molecules expression as intercellular 
adhesion molecule 1, adhesion molecule 1 
endothelial of leukocyte and the P-secretin 
in the cerebral vascularization, originating 
the inflammatory response. Subsequently, 
the genetic expression, changes in several 
compartments like phosphodiesterase 4D 
(PDE4D) increasing in mononuclear cells 
from peripheric blood (25). The cytokines 
activate the gene expression related with the 
inflammatory response like the inducible 
nitric oxide synthase and the cyclooxygenase 
2. With respect to nitric oxide, it has been 
related with neuroprotection mechanisms 
preconditioned by a possible neurogenesis 
factor, Idunna (goddess of protection and 
ever youth), named like this for the protector 
effects caused by its expression (21).
After cerebral ischemia genes related with 
the apoptosis like p53 and bax (19), proa-
poptotic factors like the tumoral necrosis 
Fas and Apo-2L, the death receptor TR3, the 
nuclear factor kB (NFkB) and genes linked 
to apoptosis 2 (ALG2) and Pip92 (26, 27) are 
activate besides these condition, it has been 
detected the antiapoptotic factors like Bcl2 
protein, the tumoral growth factor β1 (TGF- 
β1), transformation and growth factor alpha 
(TGFα), the erythropoietin and the growth 
factor related to insulin. The neuron capacity 
to express each one of these factors is related 
with its specific vulnerability to the ischemia 
and to the apoptotic or necrotic death (26). 
EXPERIMENTAL MODELS 
TO CEREBROVASCULAR DISEASE
To study the CVD, in vitro and in vivo expe-
rimental models have been used, to repli-
cate the physiopathological process after 
ischemia in the human brain. These models 
have generated information about molecu-
lar mechanisms triggered due to cerebro-
vascular disease; in addition, it has been 
possible to know the normal organization 
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of several neurotransmitter systems, neuro-
chemistry and neuropharmacology, because 
the biochemical effects in cells and tissues 
due to ischemia are replicated, constituting 
an advantage to study the CVD (28, 29). These 
experimental models allow the application of 
global study methods, where it is possible to 
study simultaneously several and different 
expressed molecules. These systems include 
gene differential analysis and RNA microarray 
assay to study changes in genetic expression 
(30) and the several effector proteins they 
codify by proteomic analysis, based on the 
identification of the proteins by mass spectro-
metry analyzing qualitative and quantitative 
changes in their expression, comparing their 
behavior like changes in synthesis or altera-
tion in posttranslational modifications in the 
presence of several experimental ischemic 
conditions (17, 31).
Several experimental studies have been made 
in rats and humans where the altered gene 
expression is analyzed with early and late 
ischemic brain conditions (32, 35), validating 
the experimental models in vitro and in vivo to 
research the CVD (36, 38), founding therapeu-
tics alternatives to several conditions when 
the CVD is present; the current treatments are 
not that all effective and time is a decisive 
factor in the CVD (14, 36, 39). One of the expe-
rimental models to study the CVD is the post 
mortem condition in humans for the precise 
information to analyze directly the molecu-
lar events originated by ischemia, before the 
total brain tissue damage and necrosis death, 
representing a great advantage due to the 
experimental control on the time (40). 
Studies realized in our laboratory with is-
chemia model in rats were analyzed with 
differential display in three cerebral regions: 
frontal, hippocampus and occipital zone with 
15 minutes of ischemia. Results showed chan-
ges in mRNA; in frontal region diminished the 
catalase gene expression involved in reactive 
oxygen species protection during ischemia; 
in the hippocampus increased the mRNA 
expression of the epithelial glycoprotein 314 
(EGP-314) and the ceruplasmin involved in the 
cellular adhesion and reactive oxygen species 
protection respectively. The protein L31 gene 
involved in proliferation process and cellular 
differentiation, increased in the same zone. 
Finally, in the occipital region diminished the 
mRNA expression of the cytochrome c oxidase 
polypeptide I, that initiates the apoptosis. 
These changes showed the several mecha-
nisms activated in different cerebral regions 
involved in the response participating in the 
damage or cell recovery (41). In addition, 
we also analyzed changes in protein levels 
in hippocampus, striatum body and parietal 
cortex, specifically the actin gamma protein 
diminished in the three cerebral regions (31), 
while in in the parietal cortex, phosphatid-
ylethanolamine binding protein 1 diminished 





Recently, gene expression massive studies 
have been made with microarray technology 
in several experimental models (17, 42-45). 
Specifically, a study with cerebral cortex cells 
of mouse cultivated in vitro subjected to 24 
hours of hypoxia showed 11, 200 genes; 1, 405 
changed their expression levels (12.5%), 26 
were induced (several involved in the cellular 
death process due to neuronal vulnerability) 
and 20 stopped their expression. Other genes 
found with changes are involved in the en-
doplasmic reticulum proteins transportation 
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during ischemia. Also changed genes involved 
in ubiquitination pathways; for degradation or 
activation of signaling intracellular pathways. 
Finally, several genes changed their expression 
involved in neuroprotection and tissue da-
mage (indirectly) expressed in non-neuronal 
hypoxic systems (46). 
Several microarray studies have been made 
with different hypoxic and ischemic condi-
tions in neonatal mice (2, 8, 24).
Another microarray study was made with 
distinct hypoxia and ischemia periods of time 
in neonatal mice (2, 8, 24). The differential 
expression of 343 genes were observed in 
cortex, hippocampus, thalamus and striatum; 
283 genes increased and 60 diminished their 
expression. The upregulated genes encode 
translational factors and intermediary me-
tabolism, while genes with down regulation 
encode to ionic and vesicular transporters, 
synaptic transmission and neurotransmitter, 
followed of changes in the expression of genes 
involved in cell signaling. It should be poin-
ted out, that early expressed genes after the 
ischemic damage are involved in transcription 
and apoptosis, and they could be proposed 
as therapeutic target (47).
In a model in vitro of neurons obtained from 
CA1, CA3 and hippocampus region submit-
ted to oxidative stress, a microarray analysis 
was made. Results showed that CA1region 
exhibited a high transcriptional activity in 
response to the oxidative stress, inflammation, 
metal transporters, ferroxidase and to the 
pre-synaptic signaling activity. While in CA3 
region, the transcriptional activity was the 
largest to potassium and calcium channels de-
monstrating that each cerebral region makes 
a different response in the same ischemia 
condition and the damage shall depend of 
their vulnerability (48). 
Mitsios in 2007 studied the gene expression 
with microarray technology in rat brains 
submitted to 1 hour of arterial occlusion with 
several days of sanguineous reperfusion (1 
hour to 21 days) and in humans with 6 hours 
after death (ischemia model) and 2 to 37 days 
of survival (sanguineous reperfusion) and 
found the reduction of the gene expression 
of 335 genes in rat and 126 genes in human; 
393 genes coincided with changes of the ex-
pression in both study systems. Whereas 184 
genes changed their expression only in the 
rat and 36 genes changes only in human and 
41 genes were down regulated in both cases, 
this study demonstrates a qualitative and 
quantitative analysis among models Used.
It has been observed that genes with changes 
in their expression in the ischemic process 
are involved in transcription, apoptosis, in-
flammation and neuroprotection (13, 45, 50). 
The most representative are shown in table 
1. Mitsios (49) analyzed 13 reports, where the 
microarray technology was applied for the ic-
tus study. These experiments were made in the 
ischemic model in rats, in post mortem cerebral 
human tissue and blood allowing an analogic 
comparison to predict the probability when 
the ischemic event will occur and validating 
the animal model to study the VCD. 
115, 347 genes have been analyzed with mi-
croarray technology, expressed genes with 
distinct ischemic condition, term of time and 
with or without sanguineous reperfusion. In 
these studies, around 28 molecules were selec-
ted to be studied in detail, and in all cases, it 
was confirmed the change of gene expression 
and their location with in situ hybridization. 
With respect to the protein codified by those 
genes, they were analyzed with different tech-
nics as Western blot, immunohistochemistry, 
RT-PCR, immunofluorescence, northern blot 
and others to find their function in cells with 
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different experimental hypoxia, ischemic and 
sanguineous reperfusion conditions (11, 49).
Recently, the changes in genetic expression 
with microarray technology were analyzed in 
anterior and posterior mice, the intensification 
of the changes after 3 hours of hypoxia and 
1 hour of oxygenation were observed. The 
increased genes are involved in the hypoxic 
response in posterior brain, and the same 
genes diminished in the anterior brain. Spe-
cifically, 1241 genes were regulated for the 
hypoxia in the cerebellum of which 642 have at 
least a binding site to the hepatic 4A receptor 
(HNF4A) and 381 have at least two binding sites 
to the same factor in their promoters, indica-
ting that HNF4A is the principal transcription 
factor for response to hypoxia in the brain 
(51). In addition, it is known that this factor 
regulates the erythropoietin expression of 
which its neuroprotector effect in the ischemic 
damage is well known (52). The differences 
of gene expression in the ischemia response 
in anterior and posterior brain, could make a 
relation among the suppression of cognitive 
functions in anterior brain and to activate 
the posterior brain functions to activate the 
survival functions (51).
THE IMPORTANCE OF THE ISCHEMIC 
PRECONDITIONING IN BRAIN 
The ischemic preconditioning (IPC) in brain, 
is a phenomenon where the neuroprotection 
is developed versus the ischemia, reducing 
the damage and neuronal death produced 
by ischemia. The IPC is induced exposing the 
cerebral tissue to other stressing factors in a 
sublethal way (12, 22). The protector effect 
of this process was described initially in the 
cardiac tissue and posteriorly, it has been 
observed in other human organs and other 
organisms (53, 55). It has described two kinds 
of protection that are variable in their tempo-
rality and in their molecular mechanisms, the 
early and late IPC. 
The effect of early IPC emerges in the first 
minutes of reperfusion and it lasts for2 to 3 
hours. The late IPC, is visible after 12 to 24 
hours after reperfusion and its effect lasts for 
2 to 3 days. The protector effects of early IPC 
are independent of the proteins synthesis, the 
effects of late IPC depend on gene activation 
and the production of new proteins (53, 56). 
El IPC is present to respond to ischemic and 
sanguineous reperfusion cycles rapidly gene-
rating the release of adenosine to the extrace-
llular space seconds after the large ischemic 
process started; this is an ATP product derived 
from its incision, it works like a signal to induce 
an intracellular message to activate the effector 
protection mechanism. The adenosine realizes 
its physiological effects through its interaction 
whit purinergic receptor A1, A2a, A2b and A3. 
The A1 and A2 have been implicated in the 
myocardium and liver IPC respectively (54). 
The response of second cellular messengers 
associated to the phospholipases C and D 
(PLC and PLD) and other systems associated 
to its activation like protein kinase C (PKC), 
amplify the signal activating transcription 
factors that activate the responses to the late 
IPC. One of the activated transcription factors 
is NFĸB, of which its translocation to nucleus 
and activates genes that codify the super oxide 
dismutase that is dependent of Mg (MgSOD), 
the inducible nitric oxide synthase (iNO) and 
the heat shock proteins (HSP) (figure 3) (54, 57).
Genes that increase their expression during 
IPC include heat shock protein families (HSP70, 
HSP27, HSP90, HSP60/HSP10 and HSP32/HO-1), 
proteins involved in translational signals (P38 
MAPK, SMAD1, guanylate cyclase, retinoic acid 
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receptor and the PLD) (58), transcription fac-
tors ( B silencer factor, C/EBO related with TF, 
c-Jun y neuro-D), regulator proteins of ionic 
homeostasis (channels of K+, Na+ y Ca+) and 
proteins involved in plasticity (TGFα, TGFβ1, 
TGBβ receptors, caspase 3, LICE, Bcl2 and BID) 
(57), all involved in the activation of cell sig-
naling pathways related directly or indirectly 
due to ischemic damage (26). 
GENOMICS OF THE ANGIOGENESIS IN 
CEREBRAL ISCHEMIA
The angiogenesis is a mechanism to generate 
new sanguineous vessels from preexisting 
ones (50, 59). The cerebral ischemia induces 
angiogenesis during the first hour that is 
present. The new created vessels will be the 
support to the new generated cells (60) and its 
induction could be part of a treatment after an 
ictus in patients (61). Then, it is so important 
to study the changes in genetic expression 
to induce or to inhibit angiogenesis (50), to 
analyze its regulation and their functional 
products (62, 63). The malformation of new 
vessels, besides the vulnerability of the pre-
existing due to ischemic damage could cause 
a cerebral hemorrhage increasing the dama-
ge; it shall depend directly on the passing of 
time after the ischemic event and the start of 
treatment (59, 64). 
After cerebral ischemia, the expression of 
multiple genes involved in the angiogenesis 
is activated and are shown in the 2 (64, 67). 
This activation has been observed in brain 
mice within 1 hour of ischemia where 42 ge-
nes related with angiogenesis increased their 
expression, of which 29 maintain their expres-
sion high for 24 hours, and 13 are activated 
for 21 days after ischemia (64) unchaining the 
formation of new sanguineous vessels (2, 50).
The therapeutic induction of angiogenesis in 
patients with ictus could be realized with rela-
ted growth factors, treatments with stem cell or 
drugs with a specific design (39, 50, 62, 68). In 
any case, the angiogenesis stimulation could 
be the beginning of an efficient neurogenesis 
(62, 69), but at the same time, an intense and 
early stimulation should be avoided, because 
it could generate abnormal structures in the 
sanguineous vessels inducing the origin or to 
aggravate a cerebral edema or hemorrhages 
in the affected zones (59, 64). 
GENOMICS OF INFLAMMATION IN THE 
CEREBRAL ISCHEMIA
During the cerebral ischemia an inflammatory 
process occurs and it could cause a rupture 
of the sanguineous vessels causing cerebral 
edema. There are genes activated specifically 
in the inflammatory process and their inhibi-
tion is studied to observe if it contributes to 
diminish the damage in the ischemic cerebral 
zone (6, 24, 70, 71).
The gene expression involved in inflammation 
has been analyzed in Wistar rats after experi-
mental subarachnoid hemorrhage and with 24 
hours of medial cerebral artery occlusion. The 
analysis of the mRNA in these models showed 
the increase in the expression of IL6, iNOS, 
chemokine ligand 2, TNFα and IL1β (13, 24). 
The gene expression of protein related with 
the extracelular matrix like MM9, MMP2 and 
MMP13 (metalloproteinases 9, 2 and 13) (72, 
73). These are induced in the cerebral arteries 
after the cerebral ischemia through the three 
intracellular pathways MAPKs; p38, ERK 1/2 
and SAPK/JNK. These pathways are activated 
in the ischemia with phosphorylation activa-
ting the transcription of factor ATF2, Alk1 and 
c-Jun, then, the gene expression related with 
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the extracellular matrix in the walls of the 
cerebral arteries (72), with the modification 
of the artery walls allow the formation of 
new sanguineous vessels that finally, shall 
permit nutrients and oxygen disposition to 
the ischemic tissue. 
Among the activated transcription factors for 
the hypoxia, related with the inflammation, 
are the NFĸB, hypoxia inducible factor 1(HIF1), 
interferon regulatory factor, among others. 
These factors activate the cytokines expression 
like TNFα, interleukins or the interferon, that 
induce the oxide nitric synthase in astrocytes 
and microglia cells, originating more free 
radicals besides the generated due to the hy-
poxia (13, 74). In the microglia, an explosion 
of proinflammatory cytokines occurs. At the 
same time, these cytokines act directly in 
endothelial cells and cause an increase in the 
permeability of the blood brain barrier. This 
process makes possible that the involved cell 
in the immune response, located in peripheric 
blood, can connect with the epithelium, to 
cross the blood brain barrier and finally, to 
migrate to the cerebral tissue affected due 
to the ischemia, where they shall make their 
function. On the other hand, it has been 
shown that transcription factors p53, PPAR 
(peroxisome proliferator-activated receptors), 
interferon regulatory factor 1 (IRF1), the sig-
nal transducer and activator transcription 3 
(STAT-3) and the nuclear factor NFĸB promote 
the expression of inflammatory genes that 
cause grave neuronal damage (70).
Finally, the increase of gene expression of IL6, 
TNFα, IL1β, MIP1α, MCP1, CXCL1, CXCL2, CCL20, 
MMP9, MMP13, VCAM1 e ICAM1, COX2, iNOS, C3 
of complement HIF1, Egr1, C/EBPβ, PPARγ, IRF1, 
STAT3, ATF3 and their subsequent increase in 
the protein level they codify, suggest that 
inflammatory response besides angiogenesis, 
could explain the reorganization occurred in 
cerebral arteries after a cerebral attack, where 
there are genes that codify for proteins invol-
ved in cellular adhesion and immune response 
(23, 62, 70, 72, 73, 75, 76).
CONCLUSIONS
The tissue response in the presence of the ische-
mic event, shall depend on the intensity of the 
immediate damage, the time passed when the 
hypoxia starts, cellular type (where the neurons 
are the most vulnerable to the ischemia process) 
will depend ofnstimulus that they will receive 
directly or indirectly from other cerebral regions 
with different damage intensity or from the 
intact cerebral regions. All these factors shall 
cause the expression of only a corresponding 
part of the genome, according to the necessary 
role to execute in the affected cells in the pre-
sence of the ischemic event, translation or not 
of the genes to proteins. On the other hand, in 
the CVD neuroprotector genes are expressed 
to resist the ischemic damage and to induce 
the cellular reparation, but also genes that de-
lete damaged cellular structures or the whole 
cell to avoid the sequential cellular death are 
expressed. At present, a variety of molecular 
mechanisms originated by the hypoxia or 
ischemia have been described; one of them is 
the genetic expression (39), allowing the origin 
of the postgenomic, where it is so important to 
complement the knowledge of the changes in 
genetic expression (63) in the presence of CVD 
to correlate with the functional proteomics 
proposing future therapeutics approaches and 
improve the treatments of this multifactorial 
disease.
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Table 1. Down regulated genes in human and rat with distinct cerebral ischemia and reperfusion 
conditions. The functions of several proteins than they codify are mentioned: stress response (a), 
receptors, transporters and channels (b) and the involved protein in the immune response (c). Mo-




HSP70a 1h- 24 h 2-6
Glucose transporter Ib 4 h- 21 days 26-37
Aquaporin 4b 3 days 9-20
Signal Translator and  
transcriptional activator 3b
4 h- 3 days 9-20
Interleukin 10c 21 days 2-20 and 26-37
Matrix metalloproteinase 14 24 h- 3 days 2-6
Glia maturation factor beta 21 days 2-6
Proto-oncogene c-jun 1 h -24 h 9-20
Table 2. Genes up regulated in the angiogénesis process due to cerebral ischemia in mouse.
Genes Role in the angiogenesis with cerebral ischemia
VEGF 
(Vascular endothelial growth factor)
The link of VEGF to its receptor on the endothelial cells 
surface, activates intracellular tyrosine kinases and signals 
to start the angiogenesis are activated.
VEGF receptor
(Vascular endothelial growth factor 
receptor)
The angiogenesis effects of VEGFR-1 (flt-1) and the VE-
GFR-2 (flk-1) occurs when they are dimerized to transmit 
de signals of VEGF.
 PDGF-β and PDGFR-β
(Platelet-derived growth factor and its 
receptor)
It could act in the endothelial cells and pericytes interac-
tion, allowing the vascular reorganization. 
TGF-β
(Transforming growth factor beta)
It regulates the cellular proliferation and differentiation. The 
mechanisms are not well known.
FGF-1 and FGF-2
(Fibroblast growth factor 1 and 2)




It stimulates the angiogenesis through the integrins signa-
ling pathways.
ANG 1 and 2
(Angiopoietin 1 and 2)
They regulate the vascular permeability and are associated 
to the angiogenesis progression through tie-2 receptor.
751Salud Uninorte. Barranquilla (Col.) 2018; 34 (3): 737-752
Applied genomic in cerebrovascular disease
Figure 1. Frequency of the cerebrovascular disease types. Is presented as cerebral ischemic cerebro-
vascular disease in a proportion of the 85% and as hemorrhagic cerebral disease with a proportion 
of the 15%. 
Figure 2. Frequency of death due to CVD and other main causes around the world (7).
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Figure 3. Molecular basis of the ischemic pre-conditioned. The corresponding mechanism to induce 
the first and second protection windows are showed. The adenosine level increase due to the ische-
mia and activate the adenosine receptors. These activate the phospholipases activity and then, the 
increase of the diacylglycerol (DAG) it promotes the protein kinase C (PKC) into cellular mem-
brane, causing several reactions no yet so clear activating the transcription factors and finally, the 
transcription of genes that codify to antioxidant enzymes (MgSOD), heat shock proteins (HSP) and 
for the inducible nitric oxide synthase (iNOS). Modified of Korthuis, 1998 (53).
